Martin Dietrich, MD, PhD, is a medical oncologist with The US Oncology Network Cancer Care Centers of Brevard and an assistant professor of internal medicine at the University of Central Florida College of Medicine in Orlando, Florida.

Factors associated with clinical outcomes in patients with HER2-mutant NSCLC treated with sevabertinib (BAY 2927088)

Funding supported by Bayer Healthcare Pharmaceuticals Inc.. Content independently developed by OncLive

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Martin Dietrich, MD, PhD presents insights from an exploratory analysis of the Phase I/II SOHO-01 trial of sevabertinib in HER2-mutant NSCLC, highlighting how clinical and molecular factors, such as prior therapy, HER2 subtype, and TP53 co-alterations, impact treatment outcomes.